NEW YORK (TheStreet) -- Provectus Biopharmaceuticals  (PVCT) plunged Wednesday after the site amended its website homepage to call PV-10 an "investigational drug for cancer" after it had previously called it a "breakthrough cancer drug."

TheStreet's Adam Feuerstein posted an article with screenshots of the two homepage descriptions and he points out Provectus is supposed to get a response from the FDA this week about its request to grant PV-10 Breakthrough Therapy status for skin cancer. The company has said nothing thus far about the FDA's response.

Seeking Alphaalso posted an extremely bearish article on Provectus on Wednesday.

Must Read: Provectus Disappears 'Breakthrough' Drug Claim on Web Site

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

TheStreet Recommends

The stock was down 18.15% to $2.21 at 12:08 p.m.

Image placeholder title

PVCT data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.